This page shows the latest Spark Therapeutics news and features for those working in and with pharma, biotech and healthcare.
patients.”. Five major pharma companies have signed up to be part of the BGTC – Biogen, Janssen, Novartis, Pfizer and Takeda – plus smaller companies like REGENXBIO, Spark Therapeutics, Taysha Gene Therapies and
bluebird bio has launched a counterclaim against Spark Therapeutics after the latter initiated a dispute a few months ago, according to Boston Business Journal. ... Spark Therapeutics is also developing a gene therapy for the potential treatment of
As part of the collaboration, Dyno will be responsible for the design of the novel AAV capsids, while Roche and its Spark Therapeutics division will develop the capsids in preclinical studies, ... This new partnership represents Dyno’s largest
Also in the running is SPK-8011 from Spark Therapeutics – although this contender suffered a setback in 2018 after two patients treated with the therapy developed immune reactions.
Pens another gene therapy deal following takeover of Spark Therapeutics. Fresh from its drawn-out takeover of Spark Therapeutics, Roche has signed another gene therapy deal, licensing Sarepta’s Duchenne muscular
Comes on the heels of CMA green light. After ten long months of waiting, Roche can finally go-ahead with its $4.3bn takeover of gene therapy specialist Spark Therapeutics, following ... with and into Spark without a vote or meeting of Spark’s
More from news
Approximately 18 fully matching, plus 36 partially matching documents found.
Recent examples of this trend can be seen in Roche’s December 2019 $4.8bn takeover of Spark Therapeutics, one of the first US gene therapy firms to succeed in obtaining
Pharma’s return? Positive data on one of the combinations or approval of aducanumab could spark renewed interest in treating Alzheimer’s. ... Such a shift has recently happened in the gene therapy space, which was a backwater pursued largely by
Meanwhile, Spark Therapeutics’ Luxturna for a hereditary eye disease (marketed by Novartis in Europe) costs around $425, 000 per eye, bringing it close to that $1m mark. ... Fellow US gene therapy company Spark was acquired by Roche for $4.3bn in
1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... Unlike fellow Boston, MA-based gene therapy company Spark
sales, and 6 are in the top 10 companies with Pfizer (with Spark Therapeutics), Novartis (by acquiring AveXis), Celgene (with Bluebird and through acquiring Juno Therapeutics), Sanofi, Roche and Merck all ... Those prices pale in comparison though when
More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.
Sigilon has already reached certain milestones for its Living Therapeutics product platform, including its Afibromer technology, which represents a new class of breakthrough implantable biomaterials. ... Vivaldi has more than 25 years’ experience and
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Barrett, HealthforAnimals, Lloyds Pharmacy, Novo Nordisk, Raisio, Roche Diagnostics, Sanofi, Seqirus, SLG, Spark Therapeutics, Superdrug, Thornton &Ross, Vetoquinol, VMIC, Zogenix.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical website. Support the...